drugset / Trial / NCT01272791
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-02
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavituximab | Monoclonal antibody | 3 mg/kg | — |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | — |